Late-onset metachromatic leukodystrophy: genotype strongly influences phenotype

H Rauschka1, B Colsch, N Baumann

  • 1Center for Brain Research, Medical University of Vienna, Department of Neurology, Hospital Lainz, Austria.

Neurology
|September 13, 2006
PubMed
Abstract

Insights

Two common mutations in late-onset metachromatic leukodystrophy (MLD), P426L and I179S, show distinct clinical patterns. P426L mutations cause motor issues, while I179S mutations lead to behavioral and mental decline.

Area of Science:

  • Genetics
  • Neurology
  • Biochemistry

Background:

  • Late-onset metachromatic leukodystrophy (MLD) exhibits significant phenotypic variability.
  • P426L and I179S are the most prevalent mutations associated with adult and juvenile MLD.
  • Understanding these mutations is crucial for diagnosing and managing MLD.

Purpose of the Study:

  • To investigate the relationship between specific genetic mutations and clinical presentation in late-onset MLD.
  • To identify genotype-phenotype correlations for P426L and I179S mutations.

Main Methods:

  • Retrospective analysis of 22 patients homozygous for the P426L mutation.
  • Review of the clinical data of 20 patients heterozygous for the I179S mutation, including their second arylsulfatase A (ASA) mutation.
  • Comparison of clinical courses, neurological examinations, and biochemical markers.

Main Results:

  • P426L homozygotes primarily exhibited progressive gait disturbances (spastic paraparesis, cerebellar ataxia) with later-onset mental decline.
  • I179S heterozygotes presented with schizophrenia-like symptoms, social dysfunction, and cognitive decline, with minimal motor deficits.
  • P426L homozygotes showed reduced nerve conduction velocities and lower residual ASA activity compared to I179S heterozygotes.

Conclusions:

  • Distinct clinical presentations differentiate homozygous P426L and compound heterozygous I179S genotypes in late-onset MLD.
  • These findings establish a clear genotype-phenotype correlation for these common MLD mutations.
  • This correlation aids in predicting disease progression and tailoring patient management.

Related Concept Videos

Genetic Lingo01:11

Genetic Lingo

Overview
Pleiotropy01:33

Pleiotropy

Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
Lethal Alleles02:41

Lethal Alleles

Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
Background and Environment Affect Phenotype02:27

Background and Environment Affect Phenotype

Although the genetic makeup of an organism plays a major role in determining the phenotype, there are also several environmental factors, such as temperature, oxygen availability, presence of mutagens, that can alter an organism’s phenotype.
An example of how genetic background affects phenotype can be seen in horses. The Extension gene in horses is responsible for their coat color. A wild-type gene (EE) produces black pigment in the coat, while a mutant gene (ee) produces red pigment. A...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pedigree Analysis01:35

Pedigree Analysis

Overview